Crown Bioscience Inc.
Crown Bioscience Releases Scientific Posters Detailing Innovations in Preclinical Cancer Pharmacology
Presentation of Posters by Expert Scientists Now Available On-Demand on Crown Bioscience's Website https://www.crownbio.com/eortc17-posters
SANTA CLARA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, releases scientific posters narrated by leading scientists . These posters were presented at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and are now available on-demand on Crown Bioscience's website, https://www.crownbio.com/eortc17-posters .
Crown Bioscience presented more than a dozen scientific posters describing innovations in the field of preclinical cancer research at AACR-NCI-EORTC 2017. The most compelling work is now available on-demand and narrated by Crown Bioscience's scientific experts. The library of poster presentations includes Dr. Henry Li presenting, "Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments" , Dr. Jie Cai describing "The World's Largest, Well-Characterized PDX Collection ", and Dr. Nektaria Papadopoulou detailing the "Interrogation of Checkpoint Inhibitors in Bioluminescent Orthotopic Syngeneic Models of Hepatocellular Carcinoma ", among others.
"I am excited to share Crown Bioscience's cutting-edge research with colleagues that were not able to attend AACR-NCI-EORTC," said Dr. Henry Li, Crown Bioscience's Vice President of Biomarker & Diagnostic Technology. "The work presented will help researchers understand how to identify critical biomarkers and improve evaluation of cancer therapies and immunotherapies."
"Crown Bioscience is committed to making valuable contributions to the scientific community," said Laurie Heilmann, Crown Bioscience's Chief Business Officer. "By providing these posters, narrated by the experts behind the science, we hope to deliver insights researchers can use to advance their preclinical drug development programs."
The library of narrated posters can be found on Crown Bioscience's website, https://www.crownbio.com/eortc17-posters .
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Venanpri Group23.3.2018 12:01 | pressemeddelelse
Agrisolutions Acquires Trinity
Crown Bioscience Inc.22.3.2018 14:45 | pressemeddelelse
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
SEMAFO Inc.22.3.2018 12:01 | pressemeddelelse
SEMAFO: Construction of Boungou Mine 87% Complete
3Gtms21.3.2018 15:02 | pressemeddelelse
3Gtms Positioned in the Niche Players Quadrant of the Gartner Magic Quadrant for Transportation Management Systems
Addivant21.3.2018 14:39 | pressemeddelelse
Addivant Announces Price Increases on Hindered Amine Light Stablizers
VistaJet Ltd21.3.2018 14:19 | pressemeddelelse
VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum